Can you drink alcohol on retatrutide?

Reviewed 21 sourcesPublished by PepVault

Retatrutide has no label, so no official alcohol rule. What its trials excluded, what the glucagon arm means for blood sugar, and what a rat study found.

Man in a white tee grills shrimp and vegetable skewers on a kettle grill on a deck
Last reviewed
Sources
21
Questions
6
Compounds
2

The short answer

Retatrutide has no label, so there is no official rule on alcohol. Its phase 2 obesity trial left out women who drank more than 14 units a week and men who drank more than 21, and its phase 3 trials left out anyone who had had pancreatitis. No study has given people retatrutide and alcohol together. Ask your prescriber before you drink, and never drink on an empty stomach.

Every number checked at its primary source · · 21 sources · How we research

Evidence: No study has given people retatrutide and alcohol together. This page rests on the trials' registered rules and results, the closest FDA labels (tirzepatide, glucagon), small human studies of alcohol and blood sugar, and one rat study of retatrutide and alcohol.

Man in a white tee grills shrimp and vegetable skewers on a kettle grill on a deck

Does retatrutide have an official alcohol warning?

No, because it has no label at all. Retatrutide is still in trials: FDA writes that it is not a component of any FDA-approved drug and has not been found safe and effective for any condition20. A label is where an alcohol warning would live, so for now the evidence is what the trials allowed, what they recorded, and what the closest approved labels say.

The closest labels are those of tirzepatide (Mounjaro and Zepbound), which acts on two of retatrutide's three receptors, GIP and GLP-1. The Zepbound label does not mention drinking at all: "alcohol" appears only as the swab and as benzyl alcohol, an inactive ingredient14. Our guide on alcohol on a GLP-1 sets the four approved labels side by side. This page adds what is specific to retatrutide: its trials' alcohol rules and its third receptor, glucagon.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's Food page keeps a water ring beside your daily food target: one tap adds a glass, so the day's fluids stay visible on a night out.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What did the retatrutide trials say about alcohol?

We read the eligibility rules of every Lilly retatrutide study on ClinicalTrials.gov, 33 records. Only two name an amount of alcohol, and both draw the line at the same place. The rule that runs through the big trials is about the pancreas, not drink.

TrialAlcohol rulePancreas or liver rule
Phase 2, obesity (338 adults)1Excluded above 14 units a week for women, 21 for menNo past acute or chronic pancreatitis
Phase 1, Chinese adults with obesity5Excluded above 21 units a week for men and 14 a week (the record does not say for whom)No current or past liver disease (no pancreas rule written)
Phase 2, type 2 diabetes2None writtenNo past pancreatitis
TRIUMPH-1, obesity3None writtenExcluded if ever had pancreatitis
TRIUMPH-2, obesity and type 2 diabetes4None writtenExcluded if ever had pancreatitis

Neither record says what a unit is, and the phase 2 protocol does not define it either1. Read as UK units of 8 g of pure alcohol6, the women's line of 14 units is about 112 g a week, or 8 US standard drinks of 14 g7, and the men's 21 is about 12; read as one drink per unit, the lines are 14 and 21 drinks. Its protocol also barred alcohol for the 8 hours before each clinic visit, and the trial left out anyone with liver disease other than fatty liver disease1.

A line in a trial's rules says who was studied, not what is safe. People who drank more than these amounts were never given retatrutide in that trial, so there is no data on them. Records read on ClinicalTrials.gov on November 20, 2026; one record sponsored by Hudson Biotech was left out, as those are mock entries.

What does retatrutide's glucagon arm mean for blood sugar when you drink?

Glucagon is the hormone that raises blood sugar, and retatrutide switches on its receptor as well as GIP's and GLP-1's11. The glucagon label spells out how it works: it acts on receptors in the liver, which breaks down its stored sugar, called glycogen, and releases glucose into the blood. It also says those stores are needed for glucagon to work8.

Alcohol hits mostly the liver's other way of keeping sugar up: making new glucose from scratch, called gluconeogenesis. In fasted healthy men, 67 g of alcohol given by drip over four hours, about five US drinks, caused low blood sugar by blocking that process9. In a study of 8 volunteers, alcohol blocked new glucose in fed and fasted people alike, but blood sugar fell only in the two who had fasted for 48 to 72 hours: in the others, sugar released from the stores covered the gap10. A review puts it the same way: drinking without food can bring on low blood sugar, most of all when the stores are low or with a sulfonylurea19.

What no one has tested is whether retatrutide's glucagon arm changes alcohol's effect on blood sugar, in either direction. So do not count on it to protect you. What the trials do show is that low sugar was rare on retatrutide alone: no severe low blood sugar in the phase 2 diabetes trial of 281 people12 or the 40-week trial of 537 people whose diabetes was treated by diet and exercise alone13. The bigger risk sits with insulin or a sulfonylurea, a tablet that pushes the pancreas to release insulin. In a Zepbound trial in people with type 2 diabetes, readings under 54 mg/dL came in 10.3% of those also on a sulfonylurea, against 2.1% of those who were not14.

Alcohol also blunts the body's counter-response to a drop and the person's awareness of it: 8 of 13 studies in type 1 diabetes found a higher risk of low sugar after drinking, and all 13 diabetes associations in that review advise drinking only with food17. In a phase 2 trial, people on retatrutide reported less appetite and hunger than on placebo21, which is exactly the low-store, no-food setting these studies describe.

Does drinking add to retatrutide's stomach side effects and fluid loss?

The overlap is in the stomach. In TRIUMPH-2, at the 12 mg dose, diarrhoea came in 34% and nausea in 28% of people, against 13% and 8% on placebo15. The tirzepatide label links kidney injury, in some cases needing dialysis, mostly to fluid lost through vomiting and diarrhoea14. A night of drinking that ends in vomiting lands in that same place.

Pancreatitis, an inflammation of the pancreas, is the other shared point. High alcohol intake is an established cause of it18, and in the two phase 2 trials, 3 of the 457 people on retatrutide had serious acute pancreatitis, against none of the 115 on placebo12. That is why the phase 3 trials leave out anyone who has had it34.

Does retatrutide make you want to drink less?

In rats, it changed how alcohol felt. In a 2025 study, 10 rats were trained to tell alcohol from water by how it felt inside. A single dose of retatrutide at 0.3 mg/kg cut their alcohol-type responses, as semaglutide and tirzepatide did, without slowing their pressing overall16. That points the same way as the semaglutide trials in people, set out in our guide on GLP-1s and alcohol cravings.

This is a rat study of one dose; no trial in people has tested retatrutide and drinking. ClinicalTrials.gov listed no such study on November 20, 2026.

Commonly reported: less wish to drink. On our retatrutide reviews page, 8 of the 98 people whose reports we read describe less wish to drink or smoke, alongside less appetite and less food noise.

How do you drink more safely on retatrutide?

  1. Ask your prescriber before you drink, and say if you take insulin or a sulfonylurea: on the closest label, those raise the low-sugar risk, and lowering their dose may lower it14.
  2. Eat before and while you drink. Every diabetes association in the review advises alcohol only with food17, and low stores are where alcohol drops sugar10.
  3. Count in standard drinks: 12 ounces of 5% beer, 5 ounces of 12% wine or 1.5 ounces of 40% spirits each hold about 14 g of alcohol7.
  4. Go easier in the first weeks and after a dose step-up: in the trials, stomach side effects rose with the dose and eased over time1315.
  5. Drink water alongside, and more on any day with vomiting or diarrhoea14.
  6. Tell the people you are with the signs of low sugar the tirzepatide label lists, such as dizziness, confusion and slurred speech14: they can pass for being drunk.

PepVault's Food page keeps a water ring beside your daily food target: one tap adds a glass, so the day's fluids stay visible on a night out. Track your food in PepVault

Log a side effect on the Side effects page with its severity and a note such as "two glasses of wine"; the symptom, severity and date go into the report you can bring to your prescriber. Log it in PepVault

When to get help As the tirzepatide label puts it, severe stomach pain that will not go away, sometimes felt through to the back, is a reason to stop and call your prescriber right away14.

Track it in the app

Sources

  1. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Eligibility criteria and results, read November 20, 2026. clinicaltrials.gov
  2. ClinicalTrials.gov NCT04867785. A study of LY3437943 in participants with type 2 diabetes (phase 2; sponsor Eli Lilly and Company). Eligibility criteria and results, read November 20, 2026. clinicaltrials.gov
  3. ClinicalTrials.gov NCT05929066 (TRIUMPH-1). A study of retatrutide in participants who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). Eligibility criteria, read November 20, 2026. clinicaltrials.gov
  4. ClinicalTrials.gov NCT05929079 (TRIUMPH-2). A study of retatrutide in participants with type 2 diabetes who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). Eligibility criteria, read November 20, 2026. clinicaltrials.gov
  5. ClinicalTrials.gov NCT05548231. A study of LY3437943 in Chinese participants with obesity or overweight (phase 1; sponsor Eli Lilly and Company). Eligibility criteria, read November 20, 2026. clinicaltrials.gov
  6. NHS. Alcohol units. nhs.uk
  7. National Institute on Alcohol Abuse and Alcoholism. What is a standard drink? niaaa.nih.gov
  8. Xeris Pharmaceuticals. GVOKE (glucagon injection), prescribing information, sections 5.4 and 12.1. DailyMed, read November 20, 2026. dailymed.nlm.nih.gov
  9. Wilson NM, Brown PM, Juul SM, Prestwich SA, Sönksen PH. Glucose turnover and metabolic and hormonal changes in ethanol-induced hypoglycaemia. Br Med J (Clin Res Ed). 1981;282(6267):849-853. PubMed 6783200
  10. Kreisberg RA, Siegal AM, Owen WC. Glucose-lactate interrelationships: effect of ethanol. J Clin Invest. 1971;50(1):175-185. PubMed 5101294
  11. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. PubMed 35985340
  12. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280
  13. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1). Lancet. 2026. PubMed 42250575
  14. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information and Medication Guide. DailyMed, version 40 (updated August 28, 2026). dailymed.nlm.nih.gov
  15. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PubMed 42810372
  16. Windram M, Lovelock DF, Carew JM, Krieman CG, Hendershot CS, Besheer J. Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats. Psychopharmacology (Berl). 2026;243(5):1185-1197. PubMed 40699363
  17. Tetzschner R, Nørgaard K, Ranjan A. Effects of alcohol on plasma glucose and prevention of alcohol-induced hypoglycemia in type 1 diabetes: a systematic review with GRADE. Diabetes Metab Res Rev. 2018;34(3):e2965. PubMed 29135074
  18. Samokhvalov AV, Rehm J, Roerecke M. Alcohol consumption as a risk factor for acute and chronic pancreatitis: a systematic review and a series of meta-analyses. EBioMedicine. 2015;2(12):1996-2002. PubMed 26844279
  19. van de Wiel A. Diabetes mellitus and alcohol. Diabetes Metab Res Rev. 2004;20(4):263-267. PubMed 15250029
  20. US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). fda.gov
  21. Kanu C, Boye KS, Poon JL, et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: results of a phase 2 study. Diabetes Obes Metab. 2025;27(12):6988-6998. PubMed 40916752

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo